Dendrimer-based magnetic resonance imaging agents for brain cancer

International audienceBrain cancer is one of the most lethal and difficult to treat cancers because of its physical location and biological barriers. The mainstay of brain cancer treatment is surgical resection, which demands precise imaging for tumor localization and delineation. Thanks to advances in bioima-ging, brain cancer can be detected earlier and resected more reliably. Magnetic resonance imaging (MRI) is the most common and preferred method to delineate brain cancer, and a contrast agent is often required to enhance imaging contrast. Dendrimers, a special family of synthetic macromolecules, constitute a particularly appealing platform for constructing MRI contrast agents by virtue of their well-defined three-dimensional structure, tunable nanosize and abundant surface terminals, which allow the accommodation of high payloads and numerous functionalities. Tuning the dendrimer size, branching and surface composition in conjunction with conjugation of MRI functionalities and targeting moieties can alter the relaxivity for MRI, overcome the blood-brain barrier and enhance tumor-specific targeting, hence improving the imaging quality and safety profile for precise and accurate imaging of brain tumors. This short review highlights the recent progress, opportunities and challenges in developing dendrimer-based MRI contrast agents for brain tumor imaging